Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2034 participants.
Also called NCT07566091
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,034 participants
- Sponsor
- Jung-min Ahn
- Registry
-
NCT07566091
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07566091. Randomized; double masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2027-06-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
- Acronym
- NOVA
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Sirolimus-Ascorbic Acid Eluting Stent
- Intervention (Device)
- Everolimus-Eluting Stent
- Lead sponsor
- Jung-min Ahn
- Collaborator
- The CardioVascular Research Foundation (CVRF)
Record details
- Record id
cardio:ct-nct07566091- Content hash
c30873fe9bcb44dcad975407a001b4c3825857ce3919c0e5839775229f047fe5